- Details
- In an informative discussion, Ashish Kamat welcomes Girish Kulkarni to discuss his work around cystectomy-free survival data and the impact of pembrolizumab monotherapy for BCG-unresponsive CIS, as presented in the KEYNOTE-057 trial. Kulkarni highlights the promising results from the trial, stating that patients who responded to the therapy had a median cystectomy-free survival time of 58 months,...
|
- Details
- In this conversation, moderated by Ashish Kamat, Paulo Gontero and Gary Steinberg, discuss the treatment and management of intermediate risk, non-muscle invasive bladder cancer (NMIBC). Gontero explains their use of the 2021 EAU guidelines to determine a patient's risk category based on several variables. He emphasizes the complexity of the intermediate risk category and the further need to sub-st...
|
- Details
- In a discussion, Ashish Kamat and Girish Kulkarni delve into the Theralase ® project of intravesical photodynamic therapy for non-muscle invasive bladder cancer. This study, led by Dr. Kulkarni, employs photo-dynamic therapy in a phase two trial for BCG unresponsive bladder cancer, with promising early results. The procedure uses a ruthenium-based photosensitizer and a laser light that creates oxy...
|
- Details
- Matt Cooperberg hosts a conversation with Drs Tracy Downs and Linda McIntire on 'Cultural Complications in Urology', a plenary session at the AUA 2023 annual meeting, which aims to shed light on the biases and barriers faced by marginalized groups in urological care. They explore a variety of patient cases, each highlighting the need for more culturally sensitive practices, with a focus on elimina...
|
- Details
- In this conversation, Ashish Kamat welcomes Andrea Necchi to present his research on the Vesical Imaging-Reporting and Data System (VI-RADS) and its correlation with the pathologic and molecular outcomes of patients undergoing perioperative IO therapy in the context of the PURE-01 study. The study focuses on the evaluation of MRI data and the response to neoadjuvant Pembrolizumab in muscle-invasiv...
|
- Details
- Matt Cooperberg interviews Sigrid Carlsson, Director of Research at MSK for Urology, on the evolution of prostate cancer screening policy and ongoing innovative trials. Carlsson, an integral member of the AUA's screening guideline panel, highlights the transition from the traditional DRE and PSA tests to a new era of risk-stratified screening, aiming to optimize the benefits of PSA testing while m...
|
- Details
- In this conversation, Siamak Daneshmand joins Sam Chang in discussing a new treatment option for bladder cancer called TAR-200. TAR-200 is a pretzel-shaped device that delivers gemcitabine, a chemotherapy drug, directly into the bladder over a specified period of time. The conversation focuses on the late-breaking abstract of the SunRISe-1 trial, which evaluates the efficacy of TAR-200 in BCG unre...
|
- Details
- Badrinath Konety and Wassim Kassouf discuss managing Bacillus Calmette–Guérin (BCG) toxicity and optimizing BCG therapy in bladder cancer with Wei Shen Tan. BCG toxicity can range from local bladder symptoms to systemic effects. Patient selection is crucial in reducing toxicity, avoiding BCG in cases of gross hematuria or symptomatic UTIs. Delaying BCG and using longer intervals between instillati...
|
- Details
- Roger Li joins Ashish Kamat in a discussion on gene therapy with CG0070 (cretostimogene) and pembrolizumab in the BCG-unresponsive CIS-containing population. Roger shares the updated results from the CORE1 trial, highlighting the good efficacy results 12 months after treatment initiation. Out of the 25 patients who reached the 12-month time point, 17 had a complete response, indicating a significa...
|
- Details
- Jeremy Teoh joins Wei Shen Tan in a discussion on a multicenter randomized control trial comparing en bloc resection to standard resection for bladder tumors less than three centimeters in size. The primary outcome was the one-year recurrence rate, and secondary outcomes included progression rate and detrusor muscle sampling. The study focused on non-muscle invasive bladder cancer and recruited 27...
|
